Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations
Read More
In The News
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Media
STX-478, a mutant-selection PI3Kα inhibitor clinical candidate with a best-in-class-profile
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile
Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile
Press Releases
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More